FEATURED
Merck KGaA Agrees to Acquire SpringWorks for $3.9 Billion
Merck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
DEALS
Merck KGaA Agrees to Acquire SpringWorks for $3.9 Billion
Merck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
PRESS RELEASES
Striatech Backs ARVO’s Rising Vision Scientist
At Striatech, advancing the future of ophthalmic research is a central commitment. In partnership with the ARVO Foundation for Eye
EDITOR’S PICKS
Application-driven Enzymes to Expedite Pharma Processes
Application-driven enzyme engineering is a new technology created by combining in silico modelling and wet-lab based enzyme screening that is
RESOURCES
Lab Automation System Accelerates Immunoassay Development
Accelerating Immunoassay Development With Automated Storage, Filling and Labeling – Case Study An HTI Automation & Mabtech Case Study The
MANUFACTURING PROJECTS
Roche to Invest $50B in US Pharma Expansion Set To Flip Trade Deficit
In a transformative move for the U.S. healthcare manufacturing sector, Roche unveiled plans to invest $50 billion in American pharmaceutical
CLINICAL TRIALS
Lilly’s Lepodisiran Slashes Heart Disease Risk Factor by 94% in Phase 2 Trial
Eli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
REGULATORY
Novartis Secures Landmark FDA Approval for Fabhalta® in Rare Kidney Disease
Novartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
SELECTED PRODUCTS
Metabolites & Impurities for Pharmaceutical Research
Expert Synthesis Solutions (ESS) is a globally trusted partner for pharmaceutical R&D professionals offering a unique catalog of high-purity metabolites,
